Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Baricitinib 2mg Initial Study	STARTED	Cutaneous LP	12
Baricitinib 2mg Initial Study	STARTED	Dose Escalation Extension Group	0
Baricitinib 2mg Initial Study	COMPLETED	Cutaneous LP	11
Baricitinib 2mg Initial Study	COMPLETED	Dose Escalation Extension Group	0
Baricitinib 2mg Initial Study	NOT COMPLETED	Cutaneous LP	1
Baricitinib 2mg Initial Study	NOT COMPLETED	Dose Escalation Extension Group	0
Baricitinib 4mg Extension Study	STARTED	Cutaneous LP	0
Baricitinib 4mg Extension Study	STARTED	Dose Escalation Extension Group	5
Baricitinib 4mg Extension Study	COMPLETED	Cutaneous LP	0
Baricitinib 4mg Extension Study	COMPLETED	Dose Escalation Extension Group	5
Baricitinib 4mg Extension Study	NOT COMPLETED	Cutaneous LP	0
Baricitinib 4mg Extension Study	NOT COMPLETED	Dose Escalation Extension Group	0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05188521/flow